Subscribe To

Price Alert Latest News Economic Calendar News

VRTX / 3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery. Read More

Demo Live Account See Partner Details

Content Topics

Crispr

Gene

Editing

Stocks

Consider

Ground

Floor

Investing

Ground floor

Stock

VRTX

Posted: Mar 6 2023, 12:13

Author Name: InvestorPlace

VRTX News

By Zacks Investment Research
November 2, 2023

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.

By Zacks Investment Research
October 27, 2023

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $355.28, denoting a -1.66% change from the preceding trading day.

By The Motley Fool
October 26, 2023

This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024

Large-cap growth stocks with wide economic moats and top-shelf management teams have outperformed this year. Vertex Pharmaceuticals, a rare disease sp

By Zacks Investment Research
October 23, 2023

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $367.66, denoting a +1.6% change from the preceding trading day.

By Zacks Investment Research
October 17, 2023

Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i

By Zacks Investment Research
October 16, 2023

Vertex Pharmaceuticals (VRTX) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $374, denoting a +0.81% change from the preceding trading day.

By The Motley Fool
October 15, 2023

Is Vertex Pharmaceuticals Stock a Buy Now?

Vertex's sales have been slowing down, and this year the top line may rise by less than 10%. The company has multiple assets in phase 3 trials, which

By Investors Business Daily
October 12, 2023

The Surprising $5 Billion Opportunity That Drove Vertex Pharmaceuticals Stock To A Record High

Almost three-quarters of prescribed pain meds are opioids, and Vertex could change that. VRTX stock broke out to a record high Thursday.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.